BioGeneration Ventures

All figures cover the European funds tracked here since 1 January 2025, whether closed or still raising, and are compiled from public sources.

Tracked funds

1

Reported volume

€12m

Latest public closing

3 Mar 2026

Reported volume sums the public fund amounts tracked here, not the manager's firm-wide assets under management, so it may differ from totals on the manager's website.

Netherlands-based venture capital firm investing in early-stage life-sciences companies.

Focus: Early-stage European biopharma, including drug discovery and development

13 July 2023: BGV Fund V closed oversubscribed at €150m, bringing funds under management above €400m (company news).